Mucosis announces pub­li­ca­tion of pre­clin­i­cal data demon­strat­ing supe­ri­or pro­tec­tion by mucos­al­ly admin­is­tered Mimopath®-based influen­za vac­cines

Groningen, The Netherlands, 3 May 2012, Dutch biotech­nol­o­gy com­pa­ny Mucosis B.V. today announced the pub­li­ca­tion in the peer-reviewed jour­nal Vaccine of pre­clin­i­cal data show­ing that FluGEM® pro­vides supe­ri­or cross-pro­tec­tion against influen­za virus. FluGEM® is a new Mimopath®-based mucos­al influen­za vac­cine that can be admin­is­tered through sim­ple droplets in the nose.
According to the report, FluGEM®, a vac­cine based on tra­di­tion­al inac­ti­vat­ed influen­za anti­gens for­mu­lat­ed with bac­teri­um-like par­ti­cles (BLPs), pro­vid­ed full pro­tec­tion in mice against both homol­o­gous and het­erol­o­gous influen­za infec­tion. Moreover, the results show more than 300-fold low­er viral titers in the lungs when com­pared to con­ven­tion­al influen­za vac­ci­na­tion. Reduction of viral lung titers more effi­cient­ly pro­tects against dis­ease, but may also result in decreased viral shed­ding, there­by increas­ing herd immu­ni­ty. The data demon­strate that Mucosis’ unique Mimopath® tech­nol­o­gy can be used to devel­op nee­dle-free vac­cines that are more effi­ca­cious than con­ven­tion­al vac­cines.
Dr. Kees Leenhouts, CSO of Mucosis: “We are extreme­ly pleased with the results of this study. It is a piv­otal step in the fur­ther val­i­da­tion of our plat­form tech­nol­o­gy for the devel­op­ment of nov­el and improved vac­cines to pro­tect against infec­tious dis­eases.”
Mucosis will con­tin­ue to devel­op the FluGEM® vac­cine can­di­date in coop­er­a­tion with cor­po­rate, gov­ern­men­tal and non-gov­ern­men­tal part­ners. The company’s lead vac­cine can­di­date based on the same Mimopath® tech­nol­o­gy, called SynGEM™, is designed to pre­vent infec­tions with Respiratory Syncytial Virus (RSV), which affect over 60 mil­lion peo­ple world­wide rang­ing from the very young to the elder­ly with more than one mil­lion hos­pi­tal­iza­tions annu­al­ly. An RSV vac­cine does not yet exist.

Leave a Reply

Your email address will not be published. Required fields are marked *